The draft guidance discusses factors that are relevant to the 22 disclosure of risk information and provides numerous examples to illustrate FDA’s thinking on these 23 factors. This guidance responds to stakeholder requests for specific guidance on how FDA evaluates 24 prescription drug and medical device promotional pieces to determine whether they adequately present 25 risk information. The recommendations contained in this draft guidance apply to promotional materials 26 directed to both consumers and healthcare professionals.
